Siga technologies inc (SIGA)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues
Total revenues

18,902

26,742

24,047

487,011

485,764

477,053

476,874

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

-

-

-

21,282

18,919

-

12,018

8,687

8,253

8,175

4,827

4,599

3,782

3,139

3,233

4,426

4,740

5,519

7,099

7,096

8,833

8,970

11,416

12,704

12,494

12,725

14,397

15,266

0

0

0

Operating expenses
Cost of sales and supportive services

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of sales and supportive services

-

-

1,755

96,184

-

95,268

95,166

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

13,261

13,252

13,583

13,501

12,989

12,879

12,332

12,311

12,489

12,303

13,485

13,246

13,927

13,713

11,840

11,306

10,160

10,582

10,415

12,429

12,635

12,646

13,929

12,809

13,176

13,119

11,552

11,476

11,784

10,967

15,188

16,019

21,895

23,931

18,959

17,224

0

0

0

Research and development

12,455

13,303

12,352

12,731

14,005

13,016

12,823

11,571

13,327

16,679

22,056

25,654

23,535

19,710

16,490

12,848

12,859

13,130

10,994

11,288

10,701

10,707

10,654

12,194

12,953

13,785

15,433

15,342

17,393

18,213

19,613

20,613

19,265

18,367

19,991

19,750

0

0

0

Patent expenses

720

726

750

762

758

789

804

869

887

909

908

887

930

909

935

900

895

1,009

932

1,044

1,035

987

1,151

1,174

1,248

1,421

1,881

1,929

2,005

1,883

1,660

1,765

1,802

1,808

1,471

1,294

0

0

0

Total operating expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Litigation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Lease termination

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Litigation accrual

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest on PharmAthene liability

-

-

-

-

-

-

-

-

-

-

-

-

-

11,668

10,743

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

PharmAthene liability interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

28,441

123,180

-

121,954

121,126

25,977

27,930

31,118

38,601

44,281

47,144

46,002

54,377

46,612

41,226

39,129

35,382

213,253

212,850

212,806

201,859

26,888

28,088

29,035

29,360

29,190

31,626

31,506

36,462

38,398

42,963

44,107

40,421

38,270

0

0

0

Operating (loss) income

-8,512

-2,322

-4,393

363,830

361,826

355,099

355,769

-18,766

-19,114

-18,849

-20,586

-22,998

-28,224

-31,014

-42,358

-37,925

-32,972

-30,953

-30,554

-208,654

-209,068

-209,667

-198,626

-22,461

-23,348

-23,516

-22,261

-22,093

-22,793

-22,535

-25,046

-25,693

-30,468

-31,381

-26,024

-23,003

0

0

0

(Loss) gain from change in fair value of warrant liability

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of Term Loan

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) from change in fair value of warrant liability

-

-

0

0

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) from change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease (increase) in fair value of common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-303

-905

-829

-804

-4,059

-17,034

-21,673

-24,436

-18,129

-3,059

0

0

0

Decrease (increase) in fair value of common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

14,858

15,769

15,833

15,785

15,657

15,478

15,275

15,088

14,898

14,758

13,289

9,646

6,004

2,395

104

10

13

266

352

458

568

455

533

721

974

1,207

1,216

922

546

172

0

0

0

-

-

-

-

-

-

Loss from change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

0

1,820

1,520

-

1,121

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

2,498

2,822

81,023

80,268

79,674

78,940

153

150

14

16

16

45

95

102

113

95

48

42

28

16

6

1

1

1

1

1

1

1

0

0

0

1

16

13

12

12

0

0

0

Reorganization items, net

-

-

-

-

-

-

-

-

-

-

-

-

-

3,716

5,647

7,596

9,418

7,811

7,705

6,058

3,908

2,126

301

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) income before income taxes

-23,914

-10,178

0

428,126

0

-

-

-41,053

-41,414

-38,329

-36,024

-35,590

-37,746

-39,684

-49,119

-45,436

-42,357

-38,989

-38,583

-215,143

-213,381

-211,934

-198,492

-22,960

-23,264

-24,795

-23,172

-22,109

-22,509

-21,903

-9,365

-5,153

-8,779

-6,932

-19,501

-23,435

0

0

0

Pre tax loss

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Benefit (provision) for income taxes

-6,145

-2,937

14,266

-10,782

-9,659

-10,168

-27,848

-2,301

-2,211

-2,093

347

209

117

13

232

302

389

461

-170

57,716

55,853

53,528

52,253

-7,389

-7,581

-7,618

-7,715

-8,495

-8,189

-7,844

-7,660

-6,717

-37,964

-36,031

-34,435

-32,907

0

0

0

Net and comprehensive (loss) income

-17,768

-7,241

49,652

438,908

435,019

421,807

359,114

-38,752

-39,202

-36,235

-36,372

-35,799

-37,864

-39,697

-49,352

-45,738

-42,746

-39,451

-38,413

-272,859

-269,234

-265,463

-250,745

-15,570

-15,683

-17,177

-15,457

-13,613

-14,319

-14,059

-13,312

-1,927

29,185

29,099

26,540

12,963

0

0

0

Loss per share: basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-0.10

-0.11

-

-0.17

-0.18

-0.19

-0.38

-0.10

-0.12

-0.13

-0.36

-4.49

-0.06

-0.06

-

-0.09

-0.06

-0.09

-

-0.06

-0.07

-0.09

-

-

-

-0.09

-

-

Weighted average shares outstanding: basic and diluted

-

-

-

-

-

-

-

-

-

-

-

78,840

78,777

-

54,284

54,216

54,114

54,097

53,919

53,589

53,504

53,507

53,504

53,414

53,252

-

52,548

52,214

51,714

-

51,639

51,638

51,637

-

-

-

-

-

-

Basic (loss) income per share (in dollars per share)

-0.11

-0.06

-0.01

-0.04

0.02

0.67

4.85

-0.09

-0.15

-

-0.12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.16

0.54

-

-0.10

-0.12

Diluted (loss) per share (in dollars per share)

-0.11

-0.05

-0.03

-0.05

-0.02

0.71

4.71

-0.09

-0.15

-

-0.12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.11

0.40

-

-0.10

-0.12

Weighted average shares outstanding: basic (in shares)

81,240

81,160

81,064

80,986

80,913

81,536

80,023

79,094

79,039

-

78,908

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50,806

50,879

-

45,509

43,620

Weighted average shares outstanding: diluted (in shares)

81,240

82,264

82,181

82,114

82,139

87,702

82,929

81,163

79,039

-

78,908

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51,987

54,671

-

45,509

43,620

Net income (loss)

-17,768

-7,241

49,652

438,908

435,019

421,807

359,114

-38,752

-39,202

-36,235

-35,176

-34,925

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,312

-1,927

29,185

29,099

26,540

12,963

0

0

0

Change in net unrealized gain (loss) on short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

Comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

Weighted average shares outstanding: basic and diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49,959

-

-

Product Sales and Supportive Services [Member]
Total revenues

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and Development [Member]
Total revenues

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product sales and supportive services
Revenue from Contract with Customer, Excluding Assessed Tax

4,160

11,190

11,110

476,060

476,060

468,918

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development
Revenue from Contract with Customer, Excluding Assessed Tax

14,742

15,552

12,936

10,950

9,704

8,135

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-